Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis.

ABSTRACT:

Introduction

Systemic lupus erythematosus (SLE) is a chronic and complex multisystem autoimmune disease with high mortality. Telitacicept is a new strategy for the treatment of SLE, inhibiting the maturity, proliferation and differentiation of B cells, and thus, reduces disease activity. However, the effectiveness and safety of telitacicept in patients with SLE are not yet established.

Methods and analysis

Five English databases (Pubmed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature) and four Chinese databases (China National Knowledge Infrastructure, Wanfang Data, China Science and Technology Journal Database and Sinomed) will be searched from database inception to 1 June 2025. Two investigat

SUBMITTER: Ren X 

PROVIDER: S-EPMC12273074 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature